Chen has experience in the synthesis of chemically diverse compounds including nucleosides, nucleotides, heterocyclics, phospholipids, and peptides, as well as experience in liquid- and solid-phase combinatorial chemistry. While at SoRI, he designed and synthesized numerous novel small-molecule leads for anti-influenza, anti-tuberculosis, anti-viral, and anti-tumor drug development.
Chen’s research has focused on the optimization of potency and selectivity of a diverse collection of RAS-inhibitory prodrugs and bioisosteres, as well as the improvement of drug-like properties such as bioavailability, delivery and distribution.
